SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to positive earnings, a raised price target from Needham, and news of a massive AI lease deal with CoreWeave. The community is discussing the potential for a short squeeze and future hyperscaler deals, with some bulls projecting significant gains while bears warn of overvaluation. Overall, sentiment is bullish, driven by the company's growth in the AI data center space.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

BITF is trending as investors react positively to news of a debt facility conversion and additional funding for HPC/AI development. The community is actively discussing the potential for significant repricing and are targeting a move past the $5 mark, driven by optimism around the company's shift towards high-performance computing and AI applications within the Bitcoin mining sector.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to a recently announced $2 billion equity offering, leading to community debate about dilution and valuation. While some view the offering, priced at a premium, as a bullish sign of investor confidence in the quantum computing company's future, others express concerns about the long-term impact on shareholders and the sector's high valuations.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, igniting discussions about future government contracts. The community is actively evaluating the company's growth potential relative to other quantum computing stocks. Many investors are describing LAES as undervalued with potential for a significant upward trajectory.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss the potential for a short squeeze, fueled by high short interest and recent positive developments, including a partnership with Google. Community members are closely monitoring resistance levels and anticipating a breakout, drawing comparisons to other AI and high-performance computing data center plays. The focus remains on the company's transition towards AI infrastructure and its potential for growth in the sector.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as discussions revolve around its potential to catch up with other miners like CLSK and IREN, with some expressing frustration over its underperformance and management. Community members are debating whether its current valuation reflects its Bitcoin holdings and future AI prospects. Short interest remains high, fueling speculation about a potential squeeze.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is surging, fueled by speculation around a potential ETF and positive technical indicators, leading to renewed interest in the crypto asset. The community is actively discussing price targets and potential breakouts, while also debating whether this rally will be sustained. Some traders are pointing to Litecoin's historical performance relative to Bitcoin, suggesting it is undervalued.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as the stock breaks through the $5 mark, exciting long-term holders who have been waiting for this milestone. The community is celebrating this surge, anticipating further gains and a continued upward trend. Positive sentiment is fueled by discussions of potential catalysts, including new deals and progress at the Clarksville facility.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as traders debate whether its recent surge is justified by fundamentals or fueled by a short squeeze, with community members highlighting both bullish and bearish arguments.  The launch of a new 2x short ETF (RGTZ) has added another layer to the discussion, as some believe it will exacerbate the squeeze while others see it as a sign of an impending reversal.  Quantum computing stocks are also in focus, and the community is comparing RGTI's valuation and potential against competitors.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals is trending following news of positive clinical data for their QRX003 treatment, specifically in a pediatric peeling skin syndrome study. The community is actively discussing the stock's low float and potential for a short squeeze, drawing comparisons to other recent low-float biotech runners. Some traders caution about dilution and the company's history, while others remain bullish, citing the potential of the treatment and market opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H.C. Wainwright raised its price target on AnaptysBio (ANAB) to $59 from $38 on Tuesday, following the company's announcement of its plan to split its business into two.The analyst kept a ‘Buy’ rating on the shares. The new price target implies a potential upside of about 154% to the stock’s closing price on Monday.AnaptysBio <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-intent-separate-biopharma-operations">stated </a>on Tuesday that its board of directors approved plans to explore separating its business into two independent, publicly traded companies. Upon completion of the split, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and Imsidolimab with Vanda, with a focus on protecting and returning their value, the company said.The royalty management company is expected to require minimal infrastructure and staff, and will operate under a new name, it added.Meanwhile, the other company, referred to as Biopharma Co., will focus on biopharmaceutical operations, including the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, such as Rosnilimab, ANB033, and ANB101. After the split, Biopharma Co. will launch with adequate capital to fund operations for at least two years and will also operate under a new name, the company stated.The separation is expected to be completed by the end of 2026. Anaptys CEO Daniel Faga is expected to continue as CEO of the biopharma company.Shares of the company traded 30% higher on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANAB">ANAB stock</a> rose from ‘bullish’ to ‘extremely bullish territory’ over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_12_21_38_PM_png_239792a64d.webp" alt="ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>ANAB's Sentiment Meter and Message Volume as of 12:21 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they now expect the stock to crater.<stembedurl>https://stocktwits.com/CommercialREbroker/message/630482537</stembedurl>ANAB stock has more than doubled this year but dropped nearly 10% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-amends-deal-with-sanofi-broadens-partnership/chDDB6dR3BH">Novavax Amends Deal With Sanofi, Broadens Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

H.C. Wainwright’s new price target of $59 implies a potential upside of about 154% to the stock’s closing price on Monday. 

Equity

Eli Lilly shares fell 0.6% in premarket trading on Wednesday as safety concerns tied to its rheumatoid arthritis drug peresolimab and mixed results from its obesity pill candidate orforglipron weighed on investor appetite.&nbsp;In the 72-week ATTAIN-1 study, orforglipron met its main goal of superior weight reduction over placebo across all three tested doses. Patients on the highest 36 mg dose lost an average of 27.3 pounds, or 12.4% of their body weight, compared with just 2.2 pounds, or 0.9%, on placebo. Almost six in ten people shed at least 10% of their weight, and about four in ten lost 15% or more.Among the 1,127 participants with prediabetes at enrollment, up to 91% of those on treatment achieved near-normal blood sugar levels at 72 weeks, compared with 42% on placebo. The trial also showed improvements in waist circumference, cholesterol, triglycerides, blood pressure, and inflammation markers.&nbsp;However, weight loss plateaued for most patients. Researchers noted that despite the 72-week duration, weight reduction was not greater than in the prior Phase 2 trial, possibly due to differences in trial design, including greater geographic diversity and a higher proportion of male participants.The main side effects were mild-to-moderate stomach issues such as nausea, constipation, diarrhea and vomiting, with between 5.3% and 10.3% of patients stopping treatment, compared with 2.7% on placebo. No liver safety signals were seen.Orforglipron, licensed from Chugai in 2018, is also in late-stage studies for type 2 diabetes, sleep apnea and hypertension. Lilly said more than 4,500 people are enrolled in its Phase 3 ATTAIN program and that a filing in diabetes is planned for 2026.TD Cowen Downplays Peresolimab ReactionSeparately, TD Cowen analysts said Tuesday that the market reaction to Eli Lilly’s peresolimab data “seems excessive,” noting that AnaptysBio’s rival PD-1 agonist rosnilimab has reported no malignancies in any of its trials.Lilly halted development of peresolimab, an experimental PD-1 agonist for rheumatoid arthritis, after a Phase IIb study raised safety concerns. While the drug was superior to placebo at week 12 across several key endpoints, its efficacy was not clearly differentiated from existing therapies.&nbsp;In addition, malignancies were reported in patients receiving peresolimab, including two cases in each of the 1,000 mg and 400 mg dose groups through week 12, and four more cases by week 60, compared with none in the placebo arm.&nbsp;Reports of possible major cardiovascular events also weighed on the program’s benefit–risk profile and contributed to the decision to stop development.On Stocktwits, retail sentiment for Lilly was ‘bearish’ amid ‘low’ message volume.<a href="https://stocktwits.com/symbol/LLY">Lilly’s stock</a> has declined 0.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Why Is Eli Lilly’s Stock Slipping Premarket?

The drugmaker’s oral GLP-1 pill orforglipron showed mixed data in a Phase 3 trial, and regulatory filing for obesity is targeted as early as next year.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from testing their experimental rheumatoid arthritis medication rosnilimab.The stock closed 7.6% higher at $23.52 on Tuesday, extending gains by another 5.1% to $24.71 in after-hours trading.A trial involving 424 patients proved that rosnilimab, a PD-1+ T cell depleter and agonist, delivered similar effectiveness to JAK inhibitors when administered&nbsp;monthly.&nbsp;Patients saw significant disease activity improvements through reductions in the Clinical Disease Activity Index (CDAI) and ACR70 response rates, which lasted for six months.The treatment-free period of up to two months showed sustained patient responses, which signals the possibility for longer dosing intervals.&nbsp;According to the company, no serious treatment-related adverse events appeared during the study, and the drug demonstrated superior tolerability compared to existing biologics and JAK inhibitors.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.One user&nbsp;suggested the stock was being "pumped" and speculated that a direct offering might follow.&nbsp;<stembedurl>https://stocktwits.com/Yukinvestor/message/616705356</stembedurl>Another user said they expected the updated data to disappoint and anticipated a potential offering.<stembedurl>https://stocktwits.com/Yukinvestor/message/616686959</stembedurl>The stock has risen 76.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo seen displayed on a smartphone screen on a desk next to a Macbook in Athens, Greece on November 12, 2022. (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering

The company reported successful mid-stage results for its rheumatoid arthritis drug rosnilimab, which matched the efficacy of JAK inhibitors with fewer side effects.

What’s the role of generative AI in drug discovery?

Investing.com -- Generative AI is emerging as a transformative long-term force in drug discovery, a field historically characterized by lengthy timelines, high costs, and low success rates.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist Vanda Pharmaceuticals and Anaptys Announce...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021.&nbsp;The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and secondary endpoints in a Phase 2b trial for moderate-to-severe atopic dermatitis, commonly known as eczema.Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_12_at_5_59_31_PM_c4fa8def22.png" alt="Screenshot 2024-12-12 at 5.59.31 PM.png" width="1318" height="324"><figcaption>ANAB sentiment meter and message volume on Dec 12 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for AnaptysBio plunged into ‘extremely bearish’ levels before the bell on Thursday, following a 20% jump in message volume in the previous session.<stembedurl>https://stocktwits.com/SurdifiedStocks/message/596025184</stembedurl><stembedurl>https://stocktwits.com/Blossom_Tradez/message/595998006</stembedurl>AnaptysBio stated that it would redirect its resources and capital toward other investigational autoimmune therapies.&nbsp;The company plans to report top-line Phase 2b data for rosnilimab in rheumatoid arthritis by February 2025 and Phase 2 data for ulcerative colitis in the first quarter of 2026.Wall Street analysts quickly adjusted their outlooks. H.C. Wainwright downgraded the stock to ‘Neutral’ from ‘Buy,’ slashing its price target from $52 to $19.&nbsp;The brokerage expressed disappointment but not surprise, citing the high-risk nature of the ANB032 program. It also lowered its probability of success estimates for rosnilimab in rheumatoid arthritis from 50% to 40% and for ulcerative colitis from 40% to 30%.Wells Fargo analyst Derek Archila lowered the firm’s price target for AnaptysBio to $40 from $56 but maintained an ‘Overweight’ rating.&nbsp;Archila noted that while the Phase 2b trial’s failure aligns with their bear-case scenario, the shares’ current valuation offers a favorable risk/reward profile ahead of upcoming Phase 2 data releases.AnaptysBio's stock has lost over 28% year-to-date as of Wednesday’s close, with the latest developments adding further pressure on its stock performance and investor confidence.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen with a computer wallpaper in the background in Athens, Greece on May 5, 2021. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated

Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts

Latest Ratings for ANAB
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy May 2021UBSInitiates Coverage OnNeutral
 View More...

What Analysts Are Saying About AnaptysBio Stock

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$31.97
Prev Close	$31.77
Open	$32.00
Dividend Yield	0.00%
50-Day Moving Average	$22.93
Beta	0.73
Avg. Volume	724,953.52
PE Ratio	-7.10

52-Week High	$36.54
52-Week Low	$12.21
Market Capitalization	$889.46M
EPS (Annual)	-$5.12
Price to Book	-19.87
Revenue Per Employee	$671,176.47
Enterprise Value/EBITDA	N/A

ANAB
AnaptysBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANAB News

ANABAnaptysBio Inc